Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Taxane-Induced Peripheral Neuropathy
NCT03782402Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dronabinol, cannabidiol in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by New York State Psychiatric Institute. Started Sep 2019; status: terminated.
02
Drugs
dronabinolcannabidiol
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03782402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782402.